NPI registry status
Active
2026 NPPES data Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician NPI 1760101778 MD
Verify on CMS → Irmak Karaca, MD
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician in New York, New York.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 40 in Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
282
Medicare Part D claims · 99 beneficiaries · Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician avg: 642
Generic prescribing
64%
generic claims · 36% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
76.5/100
▼ 7 pts below national avg 83.5 · Above neutral
Industry payments
$710.72
9 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Irmak Karaca, MD reported a CMS MIPS final score of 76.5/100 - below the 83.5 national average - and filed 282 Medicare Part D claims in 2023.
- 76.5/100
- MIPS score · -7 vs avg
- 282
- Part D claims, 2023
- 64%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Irmak Karaca, MD's MIPS score vs every measured U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure. Clinicians whose score CMS assigned without scoring any category are excluded.
77 ≥ 17th percentile 17% of 454,083 measured providers are in lower value bands
Each bar is a band; taller bars hold more measured providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative whole-score-point band: it counts only measured clinicians in lower score bands. A CMS MIPS metric is not a recommendation or a clinical-quality rating by PlainDoctor. See methodology § corpus placement.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Irmak Karaca, MD sits
This provider among uveitis and ocular inflammatory disease (ophthalmology) physician peers
Across the 20 uveitis and ocular inflammatory disease (ophthalmology) physician providers who report both Medicare Part D prescribing and a MIPS quality score, Irmak Karaca, MD writes more Part D claims than 15% of them and scores higher on MIPS quality than 15% - placing this provider in the lower-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one uveitis and ocular inflammatory disease (ophthalmology) physician peer from a representative sample of 19; the gold marker is Irmak Karaca, MD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Irmak Karaca, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Irmak Karaca, MD?
Below national averagePrimary specialty
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
Medicare Part D claims
282 56% vs specialty avg
MIPS final score
76.5/100 7 pts vs avg
Specialty distribution in New York
How Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician compares to other specialties among New York providers
Medicare quality performance, MIPS
Irmak Karaca, MD's 2023 MIPS final score plotted against the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician national average
- MIPS Final Score
- 76.5/100
- vs 83.5 national avg · 2023 performance year
MIPS final score (Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician) - 76.5/100 vs national avg 83.5
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Irmak Karaca, MD appears in the CMS NPPES registry as a Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician provider holding MD credentials at 622 W 168TH ST, New York, NY, 10032, with a listed phone of (212) 305-9535. NPI 1760101778 was issued on 08/23/2022.
Medicare Part D records for calendar year 2023 show 282 prescription claims written by this provider, covering 99 Medicare beneficiaries and totaling roughly $252K in drug spend, split 36% brand-name and 64% generic by claim count. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 76.5/100 for the 2023 performance year (Quality 74.3, Cost 44), compared with the 83.5 average among clinicians with a measured score.
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician is a narrow specialty nationwide, with 40 enrolled providers across 17 states and an average of 642 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1760101778 |
|---|---|
| Specialty | Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician |
| Credentials | MD |
| Gender | Female |
| NPI Issued | 08/23/2022 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
76.5025
Final Score
Measured-score avg: 83.5
74.3195
Quality
43.9595
Cost
100
Promoting Interoperability
Reporting: Group practice
Hospital and facility affiliations
Facilities where Irmak Karaca, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Trustees OF Columbia University IN The City OF New York
New York, NY
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Irmak Karaca, MD. Source: openpaymentsdata.cms.gov.
Total received
$711
Largest payer
Genentech USA, Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - New York NYSBPMC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 - they are NOT specific to Irmak Karaca, MD. To verify Irmak Karaca, MD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
Irmak Karaca, MD - brand share 36.0%
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician average
36% brand-name claims vs 64% generic, on 282 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
282
Total Claims
$252K
Total Drug Cost
99
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 468
- Total Day Supply
- 13,429
- Brand vs Generic
- 36% brand / 64% generic
- Brand Drug Cost
- $210K
- Generic Drug Cost
- $42K
Patient Demographics
- Average Patient Age
- 71.2 years
- Avg HCC Risk Score
- 1.55
- Gender Split
- 59% female / 41% male
- Age Distribution
- <65: 13, 65-74: 47, 75-84: 27, 85+: 12
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Irmak Karaca, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Prednisone
Prednisone
33 claims
- Prednisolone Acetate
Prednisolone Acetate
27 claims
- Methotrexate
Methotrexate
23 claims
- Ketorolac Trometha…
Ketorolac Tromethamine
20 claims
- Mycophenolate Mofe…
Mycophenolate Mofetil
19 claims
- Valacyclovir 12
Valacyclovir
12 claims
- Dorzolamide-Timolol 11
Dorzolamide-Timolol
11 claims
- Humira(Cf) Pen 11
Humira(Cf) Pen
11 claims
| Drug | Claims |
|---|---|
| Prednisone | 33 |
| Prednisolone Acetate | 27 |
| Methotrexate Methotrexate Sodium | 23 |
| Ketorolac Tromethamine | 20 |
| Mycophenolate Mofetil | 19 |
| Valacyclovir Valacyclovir Hcl | 12 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 11 |
| Humira(Cf) Pen Adalimumab | 11 |
| Neoral "Cyclosporine | N/A |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
More Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician in NY →
All providers in New York →
Compare specialties →
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Overview
How Irmak Karaca, MD fits within the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician landscape nationally.
40
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Providers in US
17
States with Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
642
Avg Claims per Provider
Irmak Karaca, MD's 282 claims are below the specialty average of 642.
Nearby Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as Karaca.
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the New York medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore New York
Frequently Asked Questions
What is Irmak Karaca, MD's specialty? ▼
Irmak Karaca, MD specializes in Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician and practices in New York, New York. Credentials: MD.
How much does Irmak Karaca, MD prescribe under Medicare Part D? ▼
In 2023, Irmak Karaca, MD wrote 282 Medicare Part D claims totaling $252K in drug costs for 99 beneficiaries.
What is Irmak Karaca, MD's Medicare quality score? ▼
Irmak Karaca, MD has a CMS MIPS Final Score of 76.5/100 (Quality: 74.3, Cost: 44). The average MIPS Final Score across the 454,083 clinicians with at least one published category score is 83.5; clinicians whose score CMS assigned without scoring any category are excluded from that average. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Irmak Karaca, MD located? ▼
Irmak Karaca, MD is located at 622 W 168TH ST, New York, NY, 10032. Phone: (212) 305-9535.
What is Irmak Karaca, MD's NPI number? ▼
Irmak Karaca, MD's National Provider Identifier (NPI) is 1760101778, issued on 08/23/2022.
Does Irmak Karaca, MD prescribe more brand-name or generic drugs? ▼
Irmak Karaca, MD's prescribing is 36% brand-name and 64% generic drugs by claim count, with $210K in brand drug costs.
How many Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician providers are there in the US? ▼
There are 40 Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician providers across 17 states in the US. The average Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician provider writes 642 Medicare Part D claims per year.
What drugs does Irmak Karaca, MD prescribe most often? ▼
Based on 2023 Medicare Part D data, Irmak Karaca, MD's most frequently prescribed drugs include Prednisone, Prednisolone Acetate, Methotrexate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Irmak Karaca, MD accept Medicare? ▼
Irmak Karaca, MD appears in CMS Medicare data with 282 Part D claims and 99 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Irmak Karaca, MD's credentials? ▼
Irmak Karaca, MD's NPI is 1760101778 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.